Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharma (NQ: INO )

4.145 +0.175 (+4.41%)
Streaming Delayed Price Updated: 1:40 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 351,827
Open 4.010
Bid (Size) 4.140 (7)
Ask (Size) 4.150 (5)
Prev. Close 3.970
Today's Range 3.970 - 4.240
52wk Range 3.850 - 14.75
Shares Outstanding 210,356,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-38.76%
-38.76%
1 Month
-27.79%
-27.79%
3 Month
-45.67%
-45.67%
6 Month
-63.16%
-63.16%
1 Year
-17.40%
-17.40%

More News

Read More
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
A Preview Of Inovio Pharmaceuticals's Earnings
Via Benzinga
The Analyst Verdict: Inovio Pharmaceuticals In The Eyes Of 4 Experts
Via Benzinga
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Via FinancialNewsMedia
Exposures COVID-19
Earnings Scheduled For November 14, 2024
Via Benzinga
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
INO Stock Earnings: Inovio Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Peering Into Inovio Pharmaceuticals's Recent Short Interest
Via Benzinga
Better Buy: Inovio Pharmaceuticals vs. Novavax
Via The Motley Fool
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst
Via Benzinga
Exposures Product Safety
Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
INO Stock Earnings: Inovio Pharmaceuticals Misses EPS for Q1 2024
Via InvestorPlace
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
Via The Motley Fool
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Inovio Pharmaceuticals Stock Is Diving Today: What's Happening?
Via Benzinga
Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Inovio Pharmaceuticals (INO) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.